Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. A letter of non-approval for parecoxib was issued by the FDA in 2005.
Used for short term perioperative pain control.
The Peking Union Medical College Hospital, Beijing, Beijing, China
Peking union medical college hospital, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, China
Department of Anaesthesia Asklepeion Voulas General Hospital, Voula Athens, Greece
Jinling Hospital, Nanjing, Jiangsu, China
Faculty of Medicine, Prince of Songkla University, Hadyai, Sonkla, Thailand
Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University., Guangzhou, Guangdong, China
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
G.Gennimatas GENERAL HOSPITAL OF THESSALONIKI, Thessaloniki, Greece
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.